Direct-acting antiviral treatment for patients with hepatocellular carcinoma

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Purpose of Review Hepatocellular carcinoma (HCC) affects a significant portion of patients with hepatitis C. The use of direct-acting antiviral (DAA) agents has transformed the disease outcomes in this patient group. Recent Findings Hepatitis C virus (HCV) response to DAAs can be affected by the presence of HCC, whereas DAA therapy may affect the risk of HCC recurrence in patients with a history of HCC. Summary Emerging data are demonstrating lower sustained virologic response (SVR) rates in patients with HCC compared with patients without HCC. Conflicting studies have also suggested that rates of HCC recurrence in patients with a history of HCC can potentially be increased or decreased on DAA therapy. This review will provide a brief overview of these data and inform practitioners on important considerations to make when prescribing DAA therapy for patients with HCV and HCC.

Original languageEnglish
Pages (from-to)132-139
Number of pages8
JournalCurrent Opinion in Gastroenterology
Volume34
Issue number3
DOIs
StatePublished - 1 May 2018

Keywords

  • Direct-acting antivirals
  • hepatitis C virus
  • hepatocellular carcinoma
  • liver transplant

Fingerprint

Dive into the research topics of 'Direct-acting antiviral treatment for patients with hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this